Davis R M Inc. Buys 2,837 Shares of Stryker Corporation $SYK

Davis R M Inc. raised its stake in Stryker Corporation (NYSE:SYK) by 2.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 141,753 shares of the medical technology company’s stock after buying an additional 2,837 shares during the period. Davis R M Inc.’s holdings in Stryker were worth $46,698,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Cetera Investment Advisers raised its position in Stryker by 16.8% during the first quarter. Cetera Investment Advisers now owns 151,677 shares of the medical technology company’s stock valued at $49,839,000 after purchasing an additional 21,777 shares in the last quarter. Aureus Asset Management LLC boosted its holdings in shares of Stryker by 18.0% in the 1st quarter. Aureus Asset Management LLC now owns 3,414 shares of the medical technology company’s stock worth $1,122,000 after purchasing an additional 522 shares in the last quarter. Sachem Hill LLC increased its position in shares of Stryker by 84.2% during the 1st quarter. Sachem Hill LLC now owns 1,687 shares of the medical technology company’s stock valued at $554,000 after purchasing an additional 771 shares during the last quarter. CI Investments Inc. raised its holdings in shares of Stryker by 6.1% during the 1st quarter. CI Investments Inc. now owns 139,310 shares of the medical technology company’s stock valued at $45,776,000 after buying an additional 8,043 shares in the last quarter. Finally, First Trust Advisors LP raised its holdings in shares of Stryker by 0.3% during the 1st quarter. First Trust Advisors LP now owns 45,377 shares of the medical technology company’s stock valued at $14,910,000 after buying an additional 139 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In other news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 323,264 shares of company stock valued at $100,659,489 over the last three months. Corporate insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on SYK shares. Citigroup cut their target price on Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. Truist Financial restated a “hold” rating and issued a $330.00 price objective (down from $380.00) on shares of Stryker in a report on Monday, May 4th. Robert W. Baird set a $385.00 price objective on shares of Stryker in a research note on Friday, May 1st. Weiss Ratings downgraded shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. Finally, Evercore set a $350.00 price target on shares of Stryker in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $392.52.

Stryker Stock Performance

Shares of SYK stock opened at $309.50 on Thursday. The stock has a fifty day moving average of $313.94 and a 200 day moving average of $335.90. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87. The firm has a market capitalization of $118.65 billion, a price-to-earnings ratio of 35.82, a PEG ratio of 2.02 and a beta of 0.77. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. During the same period in the previous year, the firm posted $2.84 earnings per share. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, research analysts expect that Stryker Corporation will post 14.99 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio is presently 40.74%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.